UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 1-38455
MorphoSys AG
(Exact name of registrant as specified in its charter)
Semmelweisstrasse 7
82152 Planegg
Germany
Telephone: +49 89-89927-0
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Ordinary Shares, no par value
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1) | ☒ | |
Rule 12g-4(a)(2) | ☐ | |
Rule 12h-3(b)(1)(i) | ☒ | |
Rule 12h-3(b)(1)(ii) | ☐ | |
Rule 15d-6 | ☐ | |
Rule 15d-22(b) | ☐ |
Approximate number of holders of record as of the certification or notice date: None*
* | MorphoSys AG merged with and into Novartis BidCo Germany AG on October 15, 2024, at which time the separate corporate existence of MorphoSys AG ended. |
Pursuant to the requirements of the Securities Exchange Act of 1934, Novartis BidCo Germany AG, as successor by merger to MorphoSys AG, has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
Novartis BidCo Germany AG As successor by merger to MorphoSys AG | ||
By: | /s/ Arkadius Pichota | |
Name: | Arkadius Pichota | |
Title: | Chief Executive Officer, Member of Management Board | |
By: | /s/ Lukas Gilgen | |
Name: | Lukas Gilgen | |
Title: | Chief Financial Officer, Member of Management Board |
Date: October 17, 2024